COYA · Coya Therapeutics, Inc.

On May 12, 2026, Coya Therapeutics, Inc. entered into a Sales Agreement with Leerink Partners LLC to sell shares of its common stock in an at-the-market (ATM) offering. The agreement allows Coya to offer and sell up to $30 million in aggregate gross proceeds of its common stock from time to time through Leerink as sales agent. The shares will be sold under an existing effective shelf registration statement on Form S-3 (File No. 333-289511) and a related prospectus supplement filed the same day. Leerink will use commercially reasonable efforts to sell the shares on the Nasdaq Capital Market, and may also purchase shares as principal under separate terms. The company will pay a 3.0% commission on gross proceeds and provide customary indemnification. The ATM facility provides Coya with flexible access to capital markets to fund its operations and development programs, though the company has no obligation to sell any shares and may suspend or terminate the agreement at any time.